Press coverage about Corium International (NASDAQ:CORI) has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Corium International earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.2360225672377 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Corium International (NASDAQ:CORI) opened at $11.22 on Friday. The company has a current ratio of 7.04, a quick ratio of 6.80 and a debt-to-equity ratio of 1.89. Corium International has a 12 month low of $2.67 and a 12 month high of $12.32.
A number of research analysts have weighed in on CORI shares. HC Wainwright set a $15.00 price objective on shares of Corium International and gave the company a “buy” rating in a research note on Friday, November 17th. Needham & Company LLC raised their price objective on shares of Corium International from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, November 20th. BidaskClub raised shares of Corium International from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. Zacks Investment Research lowered shares of Corium International from a “buy” rating to a “sell” rating in a research note on Tuesday, October 10th. Finally, ValuEngine lowered shares of Corium International from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $13.00.
WARNING: “Corium International (CORI) Given Daily News Impact Score of 0.20” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://sportsperspectives.com/2017/12/09/corium-international-cori-given-daily-news-impact-score-of-0-20.html.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.